Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.
Feiyang LiuFengming ZouCheng ChenKailin YuXiaochuan LiuShuang QiJiaxin WuChen HuZhenquan HuJuan LiuXuesong LiuLi WangJuan GeWenchao WangTao RenMingfeng BaiYujiao CaiXudong XiaoFeng QianJun TangQingsong LiuJing LiuPublished in: Therapeutic advances in medical oncology (2019)
Our results provide the basis for extending the application of axitinib to GISTs patients who are unresponsive or intolerant to the current therapies.